glp 1 and ovarian cancer GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential Underlying Molecular Pathways GLP-1 Drugs May Lower Risk

Because the improvements were observed among patients with type 2 diabetes as well, the authors believe GLP-1 receptor agonists benefits extend beyond glycemic control

The shift follows tightened priorauthorization rules as of August 2024, which already imposed stringent criteria, including a BMI of 35 or more, an in-person visit to a prescribing physician, proof of six months of lifestyle modification activities, and participation in programs like Teladoc Health to track their progress

It is possible for patients to have more than one form of CLE

Dehydration and Reduced Fluid Intake GLP-1 therapy can reduce thirst signals, and mild nausea may further limit fluid intake